EAE progression is also suppressed by treatment with the sphingosine 1-phosphate receptor 1 (S1PR1) agonist FTY720, which prevents T-cell egress from peripheral lymph nodes (4). In addition, blocking integrin α4, which promotes cell migration, suppresses progression of EAE and MS
FTY720 is now in clinical trials, and integrin α4 antibody (natalizumab) is currently used to treat MS patients. Targeting migration molecules can be quite effective in MS treatments.
Glasp is a social web highlighter that people can highlight and organize quotes and thoughts from the web, and access other like-minded people’s learning.